Methotrexate

When you come to get this medication, your height and weight will be measured to make sure you get the exact dose for your size. The medication order will then be sent to the pharmacist who will have to specially mix this medication for you. You will also need to have some blood tests done and reviewed before you can be given the methotrexate to make sure that your liver, kidney and blood are healthy before you are given this medication. This may take some time. We appreciate your patience and will do all that we can to make you comfortable during your stay. Vitamin B6 deficiency PN has been studied in an experimental rat model. Morphometric analysis demonstrated decreased nerve fiber density and increased axon-to-myelin ratio, indicative of peripheral neuropathy.140. Liver toxicity also increased significantly when Ieflunomide was added to the drug regimen of patients who were already on methotrexate and did not have LFT abnormalities. In study FOI, the only study to examine this question, 30 such patients had Ieflunomide added for a period of 6 months. While taking both drugs, 57% had LFT elevations 31.2 ULN Table 6 ; whereas only 1 fl?40to 13Y0. 3.2 Conversion from oral to subcutaneous methotrexate Patients receiving 15mg of oral methotrexate will receive the same dose. Patients receiving 15mg of oral methotrexate will receive 15mg. 4. 4.1 Side effects Potential side effects may include: Skin: Stomatitis, mouth ulceration, hair loss, herpes zoster, systemic fungal infection, accelerated nodules. Gastrointestinal: Nausea, diarrhoea Respiratory: Acute pneumonitis is rate, but should be considered if the patient has a dry cough or has experienced breathlessness. In the event of productive cough, the possibility of opportunistic infection should be considered and actively excluded. Blood: Macrocytosis, thrombocytopnia, neutropenia, agranulocytosis. Regular monitoring of Full Blood Count is required see Chesterfield Royal Hospital protocol ; . Liver: Abnormal liver function and hepatic fibrosis. Regular monitoring of Liver Function Tests is required see Chesterfield Royal Hospital protocol ; . Information for Patients Full explanation as to the potential benefits and side effects of drug. Contraceptive advice to avoid pregnancy fathering children during and for 3 months after treatment has finished. Reduced spermatogenesis may occur, but is reversible. Avoid Alcohol Reduce or stop smoking Before administration of the injection the following checks should be carried out Ascertain that monitoring of Full Blood Count & Liver Function Tests has been carried out and approved. Ask the patient if they have experienced side effects from previous doses, in particular breathlessness, dry or productive cough, mouth ulceration, nausea or any signs of infection. Check that patient has had a Chest X-ray reported as normal during the 12 months prior to commencing treatment or, if abnormal check that there is no contradiction to treatment e.g. fibrotic lung disease ; with prescribing doctor. Check that patient is not receiving treatment with phenytoin or folate antagonists such as Trimethoprim or Co-trimoxazole. If so, withhold treatment and contact doctor. If monitoring reveals any adverse effects, withhold the methotrexate and report the symptoms to the prescribing doctor. Check that patient has been prescribed Folic Acid 5mg orally to be taken the day after Kethotrexate administration.
Thermal comfort ventilation is required to provide or improve the comfort conditions of building occupants by means of physiological cooling and is often used in hot and humid climate condition. This is through elimination of the feeling of discomfort due to warmth and skin wetness or sweat by the cooling effect of air movement past the skin surface. The cooling effect is brought about by the accelerated heat dissipation from the body due to increasing the convective heat loss from the body and accelerating the evaporation of sweat from the skin as the air flows past it. Humidity levels however, play significant role in the evaporative capacity of the air. When the humidity is high, the high vapour pressure will prevent evaporation thus restricting the cooling effect unless higher air velocities are introduced. For thermal comfort ventilation, the value of local air velocities in occupied space would be more applicable than ventilation rates or air change rates. It was suggested that indoor air movement required for comfort should not exceed 1.0 m s as loose papers and light object tend to be disturbed above that velocity. However, it was found that some residents in hot and humid tropics often operate ceiling fans with velocities much higher than 1.0 m s to improve thermal comfort conditions. Szokolay 1997 rendered an air movement of 1.5 m s as still being acceptable for hot conditions. Thus, for hot humid climates, it is suggested that provisions should be made to acquire an air movement of at least between 1.0 m s to 1.5 m s in order to achieve the desirable comfort condition Samirah, 1998. And significant anaesthesiological risks. Additionally, one has to bear in mind the essentially destructive character of surgical procedures on PCOS patients. Therefore, ultralong GnRH analogue therapy can be an option in the treatment catalogue and albendazole. Group B streptococcus, or group B strep, is a bacterium that causes life- threatening infections in newborns. Group B strep can also cause disease in pregnant women, the elderly, and adults with other illnesses. Many people carry group B strep bacteria in their bodies without developing infection or illness. However, the bacteria can become deadly to people with weakened immune systems. Pregnant women can transmit group B strep to their newborns at birth. Group B strep is the most common cause of blood infections and meningitis in newborns. Most cases of group B strep disease in newborns can be prevented by giving certain pregnant women antibiotics during labor. What is group B streptococcus group B strep ; ? Group B streptococcus group B strep ; is a bacterium that causes life-threatening infections in newborn infants. Group B strep can also cause serious diseases in pregnant women, the elderly, and adults with other illnesses. The letter "B" refers to a classification of bacteria in the genus Streptococcus according to the makeup of the organism's cell wall. What kinds of illnesses does group B strep cause? In newborns, group B strep is the most common cause of sepsis infection of the bloodstream ; and meningitis infection of the lining and fluid surrounding the brain ; and a common cause of pneumonia. Group B strep disease in newborns usually occurs in the first week of life "early-onset" ; . Babies can also get a slightly less serious "late-onset" form of group B strep disease that develops a week to a few months after birth. In adults, group B strep usually causes no symptoms. However, in rare cases, it can lead to serious bloodstream infections, urinary tract infections, skin infections, and pneumonia, especially in people with weakened immune systems and other health problems, such as diabetes. How do people get infected with group B strep? Group B strep bacteria are different from many other types of bacteria that can cause disease. People can be "colonized" with group B strep. This means that they carry the bacteria in their bodies but are not infected and do not become sick. Adults can carry the bacteria in the gastrointestinal tract, genital tract, or urinary tract. About 10% to 30% of pregnant women are colonized with group B strep in the genital tract. Colonization with group B strep is usually harmless. The bacteria can become deadly, though, if something happens that allows them to invade the bloodstream. In adults, weakened immunity resulting from cancer treatment or a chronic illness can prompt an infection. More often, pregnant women who carry the bacteria can unknowingly transmit group B strep to their newborns at birth. Newborns can acquire early-onset group B strep disease either before or during delivery. The cause of late-onset disease in babies is not well understood. How is group B strep infection diagnosed? Group B strep infection is diagnosed by a laboratory test of blood or spinal fluid.
5. Side effects complications The side effects of methotrexate-misoprostol medical abortion are similar to those experienced with mifepristone-misoprostol medical abortion. A study comparing the side effects of mifepristone and methotrexate medical abortion regimens found that headaches were significantly more common after mifepristone and that diarrhea, fever, chills, and "worst" pain score were significantly more common after methotrexate.70 Management of side effects is similar to that recommended with mifepristone see Chapter 4, part C ; . Differences in recommendations regarding failed or incomplete abortion and ectopic pregnancy are discussed below. Failed or incomplete abortion In most protocols, ongoing viable pregnancy has been defined as the presence of gestational cardiac activity on transvaginal ultrasonography two weeks after methotrexate administration. Intervention for a nonviable pregnancy is not necessary and expulsion will occur with time, on average 22 to 29 days after methotrexate. Current recommendations in the United States for medical abortion with methotrexate regimens suggest waiting at least 29 to 45 days before completing a surgical evacuation, though some women do not want to wait this long and will request a surgical intervention.71 Ectopic pregnancy The use of methotrexate for early medical abortion will potentially treat an undiagnosed early ectopic pregnancy. In fact, the 50 mg m2 dose often used for medical abortion is the same as the recommended treatment for early ectopic pregnancy. B. Misoprostol Alone Misoprostol used alone for abortion is a promising alternative to mifepristonemisoprostol regimens. Studies have evaluated the efficacy of misoprostol used alone for both first and second trimester abortions. Given its wide availability, low price, and ease of use, women around the world have begun to use misoprostol without medical supervision as a means of abortion induction and strattera. Number of Students Per Academic Year Departmental Teaching Activities Medical Students Required Subjects Elective Subjects Students from Other Schools Physician Assistants Allied Health Students Graduate Medical Education First Years Residents PGY-1 ; Total Residents Clinical Fellows Postdoctoral Fellows Ph.D. Degree Students M.S. Degree Nursing Students Undergraduate Baccalaureate ; Other Specify ; TOTAL 3. Departmental Activities % Faculty Time 9 10 1 00-01 19 32 2. MM D-sacchafic acid 1, 4-lactone Sigma ; . Ultrafiltrates were analyzed by HPLC after 1-h and overnight incubations. Pharmacokinetic analysis. The ara-M and ara-H plasma concentration-time data were analyzed by noncompartmental methods 11, 21 ; . The peak concentration Cmax ; and the time to Cmax were observed values. The elimination rate constant k ; was obtained by log-linear regression analysis of the plasma concentration-time data. The half-life t1 2 ; was calculated by using the relationship tl 2 0.693 k. The area under the plasma concentration-time curve AUC ; was calculated by the trapezoidal rule by extrapolation to infinity by using k. Total body clearance CL ; of an intravenous dose was calculated by dividing dose by AUC and was expressed as total clearance per kilogram. Bioavailability was calculated as the ratio of the oral and intravenous AUCs expressed as a percentage, under the assumption that CL was constant from animal to animal and from day to day. The steady-state volume of distribution Vss ; of an intravenous dose was calculated by the following equation: Vs, CL x AUMC AUC ; , where AUMC is the area under the first moment of the concentration-time curve and indinavir.
Cyclophosphamide and methotrexate are only used for treatment of auto- immune disease not for transplant pts table 6. For malignant gliomas in adults, the nitrosoureas carmustine or lomustine ; , cisplatin, and procarbazine provide the best results 104, 93 ; . Methotrexwte is useful for lymphomas and medulloblastomas and aricept. 83% of our patients had moderate improvement 25 - 50% clearance ; and 17% had good improvement. It appears that patients with acne scars continued to show improvement over the 12-month period. Our findings should serve as an important reminder to laser surgeons to educate patients on the expectation of treatment outcome of laser resurfacing especially for acne scars. Erythema is a common post-operative complication 6, 7 ; . All our patients in the initial six weeks post treatment experience erythema. In all out patients, erythema cleared completely over six months after laser resurfacing. Hyperpigmentation has been reported to occur in 5% to 83% of patients after carbon dioxide laser resurfacing and is principally related to patient skin type 8-10 ; . Post inflammatory pigmentation is a problem among the dark-skinned Asians post operatively. About 25% of our patients' experience post inflammatory pigmentation from six weeks postoperatively with about 15% having moderately severe pigmentation. From our study, it appears that postinflammatory pigmentation following laser resurfacing among the dark-skinned Asian might not be as frequent as expected. But pigmentation may be severe in those affected. The pigmentation tends to clear slowly over the next six to 12 months. Asian patients should be warned of the potential of moderate post-inflammatory pigmentation following laser resurfacing. Vigilant sun protection and use of bleaching agents e.g. hydroquinone cream, may help to reduce the severity and frequency of pigmentation 10, 11 ; . All our patients were told to be vigilant on the use of sunscreen indefinitely. Hydroquinone 4% creams bd, are routinely prescribed after laser resurfacing to be used for at least six months. Pain was not a problem experienced by our patients. Almost all patients experienced minimal to mild pain the next day postoperatively. By seven days only two patients experienced minimal pain and the rest experienced no pain or discomfort at all. Hypopigmentation appeared to be not uncommon in our patients. It has been reported to occur after.
Hormone-refractory prostatic cancer. A Hoosier Oncology Group Study. Cancer. 1992; 70 10 ; : 2488-92. Murphy GP, Priore RL, Scardino PT. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial. Urology. 1988; 32 1 ; : 33-40. Stephens RL, Vaughn C, Lane M, Costanzi J, O'Bryan R, Balcerzak SP, et al. Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study. Cancer. 1984; 53 3 ; : 406-10. Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R. Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, Genitourinary Group prospective randomized phase III study 30865 ; . J Urol. 1993; 150 6 ; : 1840-4. Loening SA, Beckley S, Brady MF, Chu TM, Dekernion JB, Dhabuwala C, et al. Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol. 1983; 129 5 ; : 1001-6. Carducci M, Nelson JB, Saad F, Schulman C, Dearnaley DP, Sleep DJ, et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study [abstract]. Proc Soc Clin Oncol. 2004; 23: 383. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003; 21 4 ; : 679-89. Leaf AN, Propert K, Corcoran C, Catalano PJ, Trump DL, Harris JE, et al. Phase III study of combined chemohormonal therapy in metastatic prostate cancer ECOG 3882 ; : an Eastern Cooperative Oncology Group study. Med Oncol. 2003; 20 2 ; : 137-46. Small E, Rini B, Higano CS, Redfern C, Neumunaitis J, Valone F, et al. A randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer AIPCa ; [abstract]. Proc Soc Clin Oncol. 2003; 22: 382. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, et al. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup 0159, Cancer and Leukemia Group B 9480. J Clin Oncol. 2002; 20 16 ; : 3369-75. Ahmann FR, Saad F, Mercier R, Huddart RA, Roberts JT, Collier M, et al. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic hormone refractory prostate cancer HRPC ; [abstract]. Proc Soc Clin Oncol. 2001; 20: 174a. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000; 18 7 ; : 1440-50. Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, et al. Liarozole-a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology. 1998; 52 1 ; : 72-81. Weissbach L, Vogler H, Hofmann E, Knorr B. Palliative monochemotherapie des hormonrefrakt symptomat PCA's - ergebnisse einer prospektiven, randomisierten multizenterstudie. Urologe A. 1998; 37: 5.1 and trileptal. In sum, methotrexate is a very useful agent for the treatment of acute infantile leukemia and choriocarcinoma.

The dose of methotrexate on days + 1, + 3, + and + 11 will be reduced for hepatic and renal dysfunction, mucositis and for significant fluid collections ascites, pleural effusions ; as described below and antabuse.

20. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, Van Zeben D, Kerstens PJ, Hazes JM et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis the BeSt Study ; : a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90. Landew RBM, Boers M, Verhoeven AC, Westhovens R, Van de Laar MAFJ, Markusse HM et al. COBRA combination therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2002; 46: 347-56. Hertzberger-ten Cate R, Cats A. Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheum 1991; 9: 85-88. Van der Heijde DM, Van Riel PL, Nuver-Zwart IH, Gribnau FW, Van der Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; I: 1036-8. 24. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvier TK, Larsen A. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active RA: a double blind, randomised, multicentre trial. Lancet 1999; 353: 259-66. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, Van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement. Arthritis Rheum 2005; 52: 10-30. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. Two-year clinical and radiographic results from the TEMPO study, a double blind, randomized trial. Arthritis Rheum 2006; 54: 1063-74. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R, et al. The PREMIER study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early aggressive rheumatoid arthritis who had not had previous methotrexate. Arthritis Rheum 2006; 54: 26-37. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002; 29: 1989-99. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 3554-62. O'Dell. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002; 46: 283-5. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003; 48: 1771-4. Savolainen HA, Lehtimki M, Kautiainen H, Aho K, Anttila P. HLA B27: a prognostic factor in juvenile chronic arthritis. Clin Rheumatol 1998; 17: 121-4. Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V et al. Prognostic factors in juvenile arthritis: a casecontrol study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003; 30: 386-93. Kasapcopur O, Altun S, Aslan M, Karaaslan S, Kamburoglu-Goksel A, Saribas S, et al. Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1687-9. Ferruci ED, Majka DS, Parrish LA, Moroldo MB, Ryan M, Passo M et al. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2005; 52: 239-46. Zendman AJW, Van Venrooij WJ, Pruijn GJM. Use and significance of anti-CCP antibodies. Rheumatology 2006; 45: 20-25. Ravelli A, Martini A. Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol 2003; 21 Suppl 31: S89-93. 38. Fantini F, Gerloni V, Maurizio G, Cimaz R, Cristina A, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol 2003; 30: 579-84.
Double-blind studies. On the basis of safety and efficacy, methotrexate and azathioprine may be preferred. Methhotrexate has been the most widely reported drug for sarcoidosis and its use for sarcoidosis has been reviewed and buy albendazole. Various amounts of methotrexate 0.0-2.3 x 1o- mol L ; by both the Du Pont aca and the manual turbidimetric method. As expected, the aca results showed increasing protein values with increasing methotrexate, whereas the manual method gave results approximating the expected protein value irrespective of the methotrexate concentration. Metaproterenol 28 ; Metatensin Tablets 43 ; Methadone Hydrochloride 71 ; Methazolamide Tablets 57 ; Methocarbaml & Aspirin 63 ; Methocarbamol Tablets 57 ; Methotrexate 45 ; Methyclothiazide Tablets 57 ; Methyldopa & HCz 63 ; Methyldopa Tablets 57 ; Meticorten 75 ; Metoclopramide Tablets 57 ; Metoprolol Tartrate 63 ; MetroCream 39 ; MetroGel 39 ; Metrodin 76 ; Metronidazole Tablets 63 ; Metubine Iodide Vials 29 ; Mevacor Tablets 54 ; Mexiletine Hydrochloride 71 ; Mexitil Capsules 21 ; Mezlin 14 ; Micanol Cream 19 ; Micro-K 2 ; Micronase Tablets 66 ; Micronor 60 ; Midamor 54 ; Midamor Tablets 54 ; Midrin Capsules 23 ; Minitran Transdermal System 1 ; Minizide 65 ; Minocin 45 ; Minocycline HCI 74 ; Minoxidil Tablets 63 ; Mintezol 54 ; Miostat Intraocular Solution 4 ; Miradon 75 ; Mithracin 14 ; Mitomycin for Injection 16 ; Mivacron 41 ; Moban 80 ; Mobidin Tablets 12 ; Mobigesic Pain Reliever 12 ; Mobisyl Pain Relieving Cream 12 ; Modane 73 ; Modicon 60 ; Moduretic Tablets 54 ; Monocid Injection 77 ; Monoclate-P 24 ; Monodox 58 ; Mononine 24 ; Monopril Tablets 22 ; Motofen Tablets 23 ; Mucomyst 9 ; Mucosil Acetylcysteine 28 ; Mudrane 33 ; Mumpsvax 54 ; Mustargen 54 ; Mutamycin 22 ; Myambutol 45 ; Mycobutin Capsules 66 ; Mycostatin 9 ; Mycostatin Pastilles 22 ; Mydfrin 2.5% 4 ; Mydrapred 4 ; Mydriacyl 4 ; Mykrox Tablets 51 ; Myleran Tablets 41 ; Myochrysine Injection 54 ; Myoflex 57 ; Myotonachol 42 ; Mysoline 84 ; Mytelase Chloride Caplets 72 ; Mytrex Cream & Ointment 73 ; Nadolol Tablets 9 ; Nafcillin Sodium 9 ; Naftin Cream 5 ; Naftin Gel 5 ; Nalbuphine HCl Injection 3 ; Naldecon 9 ; Nalfon 29 ; Naloxone HCl Injection 84 ; Naprelan 84 ; Naprosyn 70 ; Naproxen 71 ; Naqua 75. Human pulmonary transplantation. Transplantation 1994; 57: 848851. Horning NR, Lynch JP, Sundaresan SR, Patterson GA, Trulock EP. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant 1998; 17: 761767. Onsager DR, Canver CC, Jahania MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999; 18: 448455. Vitulo P, Oggionni T, Cascina A, et al. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant 2002; 21: 435439. Garrity ER Jr, Hertz MI, Trulock EP, Keenan R, Love R. Suggested guidelines for the use of tacrolimus in lungtransplant recipients. J Heart Lung Transplant 1999; 18: 175 Shennib H, Mercado M, Nguyen D, et al. Successful treatment of steroid-resistant double-lung allograft rejection with orthoclone OKT3. Rev Respir Dis 1991; 144: 224226. Meiser BM, Uberfuhr P, Fuchs A, et al. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant 1997; 16: 795800. Cahill BC, O9Rourke MK, Strasburg KA, et al. Methotrexate for lung transplant recipients with steroid-resistant acute rejection. J Heart Lung Transplant 1996; 15: 11301137. Keenan RJ, Iacono A, Dauber JH, et al. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg 1997; 113: 335341. De Soyza A, Fisher AJ, Small T, Corris PA. Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation. J Respir Crit Care Med 2001; 164: 12091212. Valentine VG, Robbins RC, Wehner JH, Patel HR, Berry GJ, Theodore J. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest 1996; 109: 11841189. Andreu G, Achkar A, Couetil JP, et al. Extracorporeal photochemotherapy treatment for acute lung rejection episodes. J Heart Lung Transplant 1995; 14: 793796. Jordan SC, Quartel AW, Czer LSC, et al. Posttransplant therapy using high-dose human immunoglobulin intravenous gammaglobulin ; to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800805. Kesten S, Chaparro C, Scavuzzo M, Gutierrez C. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome. J Heart Lung Transplant 1997; 16: 905912. Ross DJ, Lewis MI, Kramer M, Vo A, Kass RM. FK506 rescue immunosuppression for obliterative bronchiolitis after lung transplantation. Chest 1997; 112: 11751179. Mentzer RM, Jahania M.S, Lasley RD, and the US Multicenter FK506 Study Group. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. Transplantation 1998; 65: 109113. Revell MP, Lewis ME, Llewellyn-Jones CG, Wilson IC, Bonser RS. Conservation of small-airway function by tacrolimus cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation. J Heart Lung Transplant 2000; 19: 12191223. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. J Thorac Cardiovasc Surg 1995; 110: 414. Speich R, Boehler A, Thurnheer R, Weder W. Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans: importance of dosage. Transplantation 1997; 64: 533535. Whyte RI, Rossi SJ, Mulligan MS, et al. Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. Ann Thorac Surg 1997; 64: 945948.
1 storb r, deeg hj, pepe m, et al methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given hla-identical marrow grafts for leukemia: long-term follow-up of a controlled trial.

Hydroxyurea hydrea ® -compared with methotrexate and cyclosporine, hydroxyurea is less toxic but also less effective. Peridone, droperidol, and metoclopramide in the prevention of nausea and vomiting following gynaecological surgery in day cases. Br J Anaesth 1986; 58: 879 Alon E, Himmelseher S. Ondansetron in the treatment of postoperative vomiting: A randomized, double-blind comparison with droperidol and metoclopramide. Anesth Analg 1992; 75: 5615. White PF, Watcha MF. Are new drugs cost-effective for patients undergoing ambulatory surgery? Anesthesiology 1993; 78: 25. Lerman J. Are antiemetics cost-effective for children? Can J Anaesth 1995; 42: 263 Liu K, Hsu CC, Chia YY. Effect of dexamethasone on postoperative nausea and vomiting. Br J Anaesth 1996; 76: 835 Henzi I, Walder B, Tramer MR. Dexamethasone for the prevention of postoperative nausea and vomiting: A quantitative systematic review. Anesth Analg 2000; 90: 186 Sehine I, Nishiwaki Y, Kakinuma R, Kibota K, Hojo F, Matsumoto T, et al. Phase II study of high-dose dexamethasone-based association in acute and delayed highdose cisplatin-induced emesis -- JCOG study 9413. Br J Cancer 1997; 76: 90 Liu K, Hsu CC, Chiba YY. Effect of dexamethasone on postoperative emesis and pain. Br J Anaesth 1998; 80: 85 Wang JJ, Ho ST, Liu YH, Lee SC, Liu YC, Liao YC, et al. Dexamethasone reduces nausea and vomiting after laparoscopic cholecystectomy. Br J Anaesth 1999; 83: 7725. Wang JJ, Ho ST, Lee SC, Liu YC, Liu YH, Liao YC. The prophylactic effect of dexamethasone on postoperative nausea and vomiting in women undergoing thyroidectomy: A comparison of droperidol with saline. Anesth Analg 1999; 89: 200 Splinter WM, Roberts DJ. Dexamethasone decreases vomiting by children after tonsillectomy. Anesth Analg 1996; 83: 913 Fredrikson M, Mursti T, Furst C, Steineck G, Borjeson S, Wikblom M, et al. Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion. Br J Cancer 1992; 65: 779 Aapro MS, Plezia PM, Alberts DS, Graham V, Jones SE, Surwit EA, et al. Double-blind cross-over study of the antiemetic efficacy of high dose dexamethasone versus high dose metoclopramide. J Clin Oncol 1984; 2: 466 Livrea P, Trojano M, Simone IL, Zimatore GB, Logroscino GC, Pisicchio L, et al. Acute changes in bloodCSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. J Neurol 1985; 231: 336 Wang JJ, Ho ST, Lee SC, Liu YC, Ho CM. The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: A doseranging study. Anesth Analg 2000; 91: 1404 Schimmer BP, Parker KL. Adrenocorticotropic hormone. Leukemia : Acute lymphoblastic leukemia in pediatric patients and young adolescents is the most responsive to present day chemotherapy . In young adults and older patients, clinical remission is more difficult to obtain and early relapse is more common . Methotrexate alone or in combination with steroids was used initially for induction of remission in acute lymphoblastic leukemias . More recently corticosteroid therapy, in combination with other antileukemic drugs or in cyclic combinations with methotrexate included, has appeared to produce rapid and effective remissions. When used for induction, methotrexate in doses of 33 mg M2 of prednisone, given daily, produced remissions in 50% of mg m2 in combination with 60 patients treated, usually within a period of 4 to weeks. Methotrexate in combination with other agents appears to be the drug of choice for securing maintenance of drug-induced remissions . When remission is achieved and supportive care has produced general clinical improvement, maintenance therapy is initiated, as follows : Methotrexate is administered 2 times weekly either. Although he never got a write-up for fighting or causing trouble. Dkt. # 6 at 3-4. ; Plaintiff further asserts a right to a hearing for infractions that jeopardize custody levels. Defendants acknowledge that Lirman authorized Plaintiff's placement in and release from the medical units on June 3, 2005, July 6, 2005, July 11, 2005, and March 10, 2005. Dkt. # 20 at 5 ; However, Defendants contend that Lirman was not involved in any other classification, security level, or location decisions related to Plaintiff and did not participate in any infraction reports prepared by Department of Adult and Juvenile Detention Officers. Id. ; To establish liability under 1983, Plaintiff must show how individually named defendants caused or personally participated in causing the harm alleged in the complaint. See Arnold v. IBM, 637 F.2d 1350, 1355 9th Cir. 1981 ; . As discussed in subsection 1, supra., Plaintiff has failed to demonstrate a constitutional violation based on Lirman's authorization of his transfer to the medical unit for monitoring of his blood glucose levels. Moreover, other than his unsupported allegations, Plaintiff has not provided any evidence showing that Lirman personally participated in or caused him to be moved to a closed custody classification. Accordingly, the undersigned concludes that Defendants are entitled to summary judgment on this claim. B. CLAIMS AGAINST DEFENDANT HOLTGEERTS In his amended complaint, Plaintiff claims that Commander Holtgeerts refused to address these issues and has allowed classification to change his status without just cause. Dkt. # 6 at 5. ; However, in response to Defendants' summary judgment motion, Plaintiff contends that defendant Holtgeerts was never brought into this matter. Dkt. # 23 at 2. ; defendant cannot be held liable under 1983 solely on the basis of supervisory responsibility or respondeat superior. See Monell v. New York City Dept. Of Social Services, 436 U.S. 658, 691 1978 ; . A supervisor is only liable for the constitutional violations of his REPORT AND RECOMMENDATION Page - 9. Upset stomach antidiarrheal GasX, Tums, Pepto-Bismol. ; Yes No If Yes: My child has taken this before Yes No My child has had a reaction to this medication Yes No If yes, please give details of the reaction.